Skip to main content

Table 1 Regulation of 38 barrier targets on the mRNA level in hCMEC/D3 samples, which were treated either with 5% FCS, 0.25% FCS or 0.25% FCS plus 100 nM hydrocortisone (HC) in EBM-2 medium prior OGD treatment

From: The pivotal role of micro-environmental cells in a human blood–brain barrier in vitro model of cerebral ischemia: functional and transcriptomic analysis

Day 5 on 65% EBM-20.25% EBM-20.25% EBM-2 + HC5% EBM-20.25% EBM-20.25% EBM-2 + HC5% EBM-20.25% EBM-20.25% EBM-2 + HC
5 h treatment5% EBM-20.25% EBM-20.25% EBM-2 + HCDMEM + GluDMEM + GluDMEM + GluDMEM–GluDMEM–GluDMEM–Glu
Normoxia/OGDNNNNNNOGDOGDOGD
Claudin-10.63 ± 0.10*0.62 ± 0.07*0.46 ± 0.07*0.94 ± 0.101.00 ± 0.000.92 ± 0.150.83 ± 0.07*§1.52 ± 0.10*0.77 ± 0.06*§
Claudin-31.25 ± 0.241.89 ± 0.881.83 ± 0.530.80 ± 0.141.00 ± 0.001.38 ± 0.320.58 ± 0.280.44 ± 0.11*1.86 ± 0.93
Claudin-41.28 ± 0.241.49 ± 0.311.97 ± 0.42*0.85 ± 0.081.00 ± 0.001.19 ± 0.170.66 ± 0.220.59 ± 0.07*1.92 ± 0.89
Claudin-51.17 ± 0.261.51 ± 0.473.00 ± 0.72*1.03 ± 0.111.00 ± 0.001.42 ± 0.301.31 ± 0.321.35 ± 0.14*3.98 ± 1.40
Claudin-61.48 ± 0.491.93 ± 0.862.54 ± 0.980.97 ± 0.191.00 ± 0.001.43 ± 0.401.39 ± 0.701.07 ± 0.185.66 ± 3.09
Claudin-71.41 ± 0.221.14 ± 0.081.21 ± 0.08*1.28 ± 0.151.00 ± 0.000.97 ± 0.110.96 ± 0.090.88 ± 0.101.08 ± 0.22
Claudin-87.28 ± 4.897.41 ± 4.0618.02 ± 12.192.09 ± 1.761.00 ± 0.003.13 ± 1.8110.05 ± 8.272.40 ± 0.9553.64 ± 35.49
Claudin-93.25 ± 1.483.93 ± 2.0412.19 ± 8.171.20 ± 0.601.00 ± 0.001.82 ± 0.635.44 ± 4.160.80 ± 0.1620.00 ± 13.21
Claudin-10 tva3.91 ± 2.464.77 ± 2.169.09 ± 5.881.31 ± 1.021.00 ± 0.001.96 ± 1.115.58 ± 4.601.96 ± 0.7429.76 ± 19.82
Claudin-10 tvb14.02 ± 8.928.74 ± 5.7326.92 ± 18.184.12 ± 3.571.00 ± 0.004.53 ± 2.5111.80 ± 10.292.21 ± 0.7961.32 ± 40.30
Claudin-111.02 ± 0.130.81 ± 0.05*0.58 ± 0.06#*1.28 ± 0.181.00 ± 0.000.78 ± 0.05*0.66 ± 0.05*0.82 ± 0.090.54 ± 0.06*§
Claudin-12 tv11.43 ± 0.12*1.48 ± 0.18*1.78 ± 0.14*0.98 ± 0.081.00 ± 0.001.00 ± 0.100.83 ± 0.05*1.00 ± 0.121.06 ± 0.09
Claudin-12 tv21.73 ± 0.21*1.72 ± 0.19*1.96 ± 0.08*1.17 ± 0.131.00 ± 0.001.07 ± 0.131.27 ± 0.09*§1.87 ± 0.19*1.98 ± 0.28*
Claudin-12 tv31.17 ± 0.161.26 ± 0.131.31 ± 0.04*1.14 ± 0.121.00 ± 0.000.95 ± 0.100.99 ± 0.08§1.63 ± 0.14*1.49 ± 0.24
Claudin-141.22 ± 0.140.77 ± 0.140.84 ± 0.131.01 ± 0.071.00 ± 0.001.16 ± 0.290.75 ± 0.08*0.99 ± 0.160.52 ± 0.07*§
Claudin-151.01 ± 0.130.90 ± 0.121.77 ± 0.471.17 ± 0.07*1.00 ± 0.001.41 ± 0.340.81 ± 0.12§1.22 ± 0.141.88 ± 0.22*§
Claudin-161.81 ± 0.28*1.62 ± 0.321.25 ± 0.200.99 ± 0.111.00 ± 0.001.07 ± 0.210.70 ± 0.05*§1.08 ± 0.110.66 ± 0.12*§
Claudin-1712.78 ± 8.6311.44 ± 8.0835.16 ± 24.624.33 ± 3.991.00 ± 0.005.63 ± 3.5920.47 ± 18.102.14 ± 0.57119.56 ± 83.89
Claudin-18 tva1.16 ± 0.261.07 ± 0.232.97 ± 1.201.09 ± 0.131.00 ± 0.001.97 ± 0.700.23 ± 0.07*0.31 ± 0.08*0.88 ± 0.39
Claudin-18 tvb1.53 ± 0.573.03 ± 1.254.07 ± 2.790.61 ± 0.271.00 ± 0.000.77 ± 0.251.89 ± 1.371.07 ± 0.338.96 ± 5.38
Claudin-201.24 ± 0.171.19 ± 0.272.04 ± 0.590.66 ± 0.13*1.00 ± 0.001.77 ± 0.490.25 ± 0.10*0.38 ± 0.12*0.63 ± 0.22
Claudin-220.81 ± 0.110.85 ± 0.081.18 ± 0.160.99 ± 0.101.00 ± 0.001.14 ± 0.170.62 ± 0.12*0.93 ± 0.141.57 ± 0.45
Claudin-230.82 ± 0.08*0.99 ± 0.070.92 ± 0.210.80 ± 0.151.00 ± 0.000.70 ± 0.170.64 ± 0.15*0.95 ± 0.161.72 ± 0.76
Claudin-240.87 ± 0.150.98 ± 0.281.51 ± 0.311.05 ± 0.131.00 ± 0.001.62 ± 0.360.57 ± 0.17*0.81 ± 0.132.34 ± 0.98
Claudin-253.47 ± 1.948.17 ± 4.468.08 ± 5.391.04 ± 0.651.00 ± 0.001.77 ± 0,764.02 ± 2.933.39 ± 0.1422.29 ± 14.18
ZO-10.80 ± 0.150.65 ± 0.06*1.16 ± 0.421.20 ± 0.201.00 ± 0.001.78 ± 0.560.86 ± 0.111.53 ± 0.331.62 ± 0.33
ZO-20.81 ± 0.08*0.93 ± 0.081.26 ± 0.170.99 ± 0.091.00 ± 0.001.16 ± 0,190.86 ± 0.08§1.39 ± 0.14*1.61 ± 0.21*
ZO-31.21 ± 0.242.12 ± 0.703.81 ± 0.96*1.37 ± 0.391.00 ± 0.003.39 ± 0.72*0.79 ± 0.21§1.71 ± 0.30*2.80 ± 0.42*
JAM-10.90 ± 0.07#1.27 ± 0.11*1.42 ± 0.08*0.94 ± 0.121.00 ± 0.001.14 ± 0.180.56 ± 0.05*§0.80 ± 0.07*0.87 ± 0.12
JAM-20.69 ± 0.311.23 ± 0.241.92 ± 0.42*1.45 ± 0.701.00 ± 0.000.84 ± 0.230.79 ± 0.131.30 ± 0.210.54 ± 0.13*§
JAM-30.91 ± 0.121.43 ± 0.391.13 ± 0.111.05 ± 0.131.00 ± 0.000.94 ± 0.070.84 ± 0.081.13 ± 0.111.42 ± 0.22
Occludin0.89 ± 0.100.78 ± 0.06*1.23 ± 0.291.00 ± 0.121.00 ± 0.001.67 ± 0.540.85 ± 0.10§1.28 ± 0.151.23 ± 0.15
Tricellulin1.00 ± 0.071.21 ± 0.112.56 ± 0.980.84 ± 0.091.00 ± 0.001.56 ± 0.400.74 ± 0.05*§1.05 ± 0.071.27 ± 0.14
CDH50.81 ± 0.090.83 ± 0.03*1.04 ± 0.260.94 ± 0.091.00 ± 0.001.11 ± 0.270.80 ± 0.05*§1.23 ± 0.09*1.05 ± 0.14
ABCB1 (PgP)0.82 ± 0.110.79 ± 0.06*1.81 ± 0.531.30 ± 0.161.00 ± 0.001.61 ± 0.501.01 ± 0.091.07 ± 0.131.41 ± 0.19
ABCC1 (MRP1)1.28 ± 0.161.00 ± 0,102.31 ± 0.961.20 ± 0.101.00 ± 0.001.88 ± 0.711.13 ± 0.191.27 ± 0.09*1.48 ± 0.16*
ABCC2 (MRP2)1.22 ± 0.12#0.94 ± 0.03*1.45 ± 0.371.25 ± 0.141.00 ± 0.001.45 ± 0.600.99 ± 0.071.13 ± 0.121.04 ± 0.16
ABCC3 (MRP3)0.91 ± 0.100.91 ± 0.062.19 ± 0.16#*0.85 ± 0.091.00 ± 0.001.94 ± 0.41*0.66 ± 0.07*0.72 ± 0.04*1.65 ± 0.28*§
ABCC4 (MRP4)0.65 ± 0.06*0.68 ± 0.02*1.33 ± 0.301.01 ± 0.091.00 ± 0.001.32 ± 0.370.55 ± 0.05*0.59 ± 0.06*0.74 ± 0.12
ABCC5 (MRP5)1.27 ± 0.211.14 ± 0.072.54 ± 0.901.22 ± 0.131.00 ± 0.001.52 ± 0.501.11 ± 0.111.45 ± 0.15*1.88 ± 0.24*
ABCG2 (BCRP)1.04 ± 0.101.14 ± 0.081.48 ± 0.16*1.01 ± 0.101.00 ± 0.001.20 ± 0.261.04 ± 0.071.28 ± 0.151.49 ± 0.25
SLC2A1 (Glut1)1.41 ± 0.16#*0.85 ± 0.07*0.85 ± 0.151.00 ± 0.101.00 ± 0.001.19 ± 0.252.62 ± 0.36*3.63 ± 0.42*4.09 ± 0.51*
VEGFa2.93 ± 0.50*1.26 ± 0.141.25 ± 0.361.06 ± 0.111.00 ± 0.001.29 ± 0.404.46 ± 0.62*5.63 ± 0.49*5.83 ± 0.57*
  1. Data were normalized on β-actin (n = 8 from four independent experiments). Claudin-2 und—19 were not detected, claudin-13 and -21 are not present in human, tv = transcript variant. Data are presented as mean ± SEM of the x-fold regulation related to hCMEC/D3 cells, which were cultivated from day 5 to 6 in EBM-2 with 0.25% FCS, their medium was changed on day 6 in DMEM plus glucose and treated for 5 h under normoxic conditions. Statistically significant regulations were marked with: *p < 0.05 versus 0.25% EBM-2 (day 5 to 6) and DMEM + Glu (5 h treatment) and N (normoxia); #p < 0.05 versus 0.25% EBM-2 (day 5 to 6) and 0.25% EBM-2 (5 h treatment) and N (normoxia); §p < 0.05 versus 0.25% EBM-2 (day 5 to 6) and DMEM—Glu (5 h treatment) and OGD (oxygen/glucose deprivation